TradeFlare's AI research teams analysed PTGX on 13 market nights between April 27, 2026 and September 18, 2026. Each row is that night's verdict, the price that day, and how the price actually moved afterwards — wins and misses alike. Nothing is edited after the fact.
| Date | Verdict | Price | Target / stop | 5 days later | 20 days later | Why (that night) |
|---|---|---|---|---|---|---|
| September 18, 2026 | BUY | $143.70 | $158.07 / $122.15 | -0.8% | not yet | The fundamental strength and positive sentiment suggest a medium-term upward trend, while the technical setup indicates an immediate bounce opportunity. |
| September 3, 2026 | BUY | $146.08 | $167.99 / $124.17 | -0.4% | -5.9% | The fundamental and sentiment tailwinds suggest a medium-term upward trend, but technicals and risk warrant a cautious approach. |
| August 31, 2026 | BUY | $144.33 | $173.20 / $122.68 | -1.2% | -4.6% | The setup is based on a technical pullback with fundamental and sentiment support, suggesting a medium-term recovery. |
| July 8, 2026 | BUY | $140.85 | $166.20 / $117.72 | -3.3% | -2.0% | The technical setup suggests a continuation of the current momentum, and the fundamental and sentiment factors support a medium-term upward trend. |
| June 23, 2026 | BUY | $115.03 | $130.00 / $96.90 | +3.0% | +13.8% | The setup suggests a potential breakout continuation driven by fundamental strength and positive sentiment, which typically plays out over a few weeks. |
| June 22, 2026 | BUY | $112.86 | $130.48 / $96.48 | +5.7% | +20.2% | The stock is showing momentum near a 52-week high, suggesting a short-to-medium term upward trend. |
| June 19, 2026 | BUY | $112.86 | $130.00 / $96.48 | +5.7% | +20.2% | The scanner trigger indicates a momentum continuation signal, and the fundamental and sentiment teams are bullish, suggesting a potential for upward price movement over a few weeks. |
| June 10, 2026 | BUY | $105.87 | $125.00 / $90.00 | +5.4% | +24.2% | The stock is near its 52-week high with strong fundamental and sentiment support, suggesting potential for continued upward momentum. |
| May 6, 2026 | BUY | $99.21 | — / — | -0.1% | -1.1% | Positive clinical trial data readouts. |
| May 5, 2026 | BUY | $99.52 | — / — | +0.8% | -3.8% | Continued positive impact from the FDA approval of ICOTYDE™. |
| May 4, 2026 | HOLD | $98.37 | $103.88 / $84.01 | +4.0% | -6.3% | The neutral market regime and the high risk score with only one bullish team necessitate a cautious approach, waiting for clearer signals. |
| April 28, 2026 | BUY | $98.51 | — / — | -2.0% | +1.0% | Continued positive developments in Icotyde's commercialization and pipeline expansion. |
| April 27, 2026 | HOLD | $100.00 | — / — | +1.0% | +1.5% | Positive clinical trial data for key drug candidates. |
Prices are daily closes. "Days later" counts trading days from the close on the day of the call. A HOLD is not a recommendation to buy; only published signals are tracked with a target and stop on the public record. How the research works. Updated October 14, 2026. AI-generated research for educational purposes — it can be wrong and is not financial advice.